In September we wrote about the Pharmaceuticals sector and its inability to gain traction due to relentless weakness in many components, particularly its largest component, Sun Pharmaceuticals.
Over the last two months the sector is basically flat, but several signs have emerged to suggest that we’re potentially at a major inflection point.
With that as our backdrop, let’s get into the charts. [Read more…]